© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Menatetrenone, known by many as vitamin K2-4 or MK-4, didn’t pop up overnight in the world of medicine and nutrition. Japanese scientists in the mid-20th century started studying fermented foods, especially their uses in preventing bleeding disorders. They found that natto, a sticky fermented soybean dish, had potent antihemorrhagic effects. Through fermentation, certain types of bacteria convert phylloquinone (vitamin K1) into menatetrenone, which showed greater activity in human blood coagulation factors. Over decades, Japanese pharmacopoeias started listing menatetrenone as a distinct therapeutic compound, with research shifting from nutrition to orthopedics when clinicians noticed connections between vitamin K2 deficiency, bone mineral density, and fracture rates among the elderly. By the 1980s, prescription formulations hit Japanese pharmacies, and since then, various regions have considered it for osteoporosis and vascular health.
Menatetrenone turns up most often as small, yellow crystals or capsules—either as supplements or pharmaceutical preparations. Manufacturers list it under many names on product labels: MK-4, menatetrenone, vitamin K2, and sometimes menaquinone-4. Unlike synthetic vitamin K1, menatetrenone comes from fermentation or chemical synthesis, packed primarily in softgels, tablets, and injectable solutions depending on the application. Some brands tout its role in bone and arterial health, pointing to studies that compare it favorably to other vitamin K forms. Its structure holds four isoprene units bound to a naphthoquinone ring, distinguishing it from other K compounds. That distinct tail gives it unique biological actions and determines which tissues can use it efficiently.
Pure menatetrenone appears as yellow to orange-yellow crystalline powder with a faintly musty odor and slight solubility in water. Its melting point hovers near 50°C, and it dissolves readily in fats and organic solvents like chloroform and hexane. Chemically, menatetrenone’s backbone is 2-methyl-3-all-trans-decaprenyl-1,4-naphthoquinone, with the four repeating isoprene units granting it high lipophilicity. This fat-solubility helps more of the compound end up in the body’s fatty tissues like the brain, arteries, and bone compared to its water-soluble siblings. UV, light, and oxygen threaten its stability, so proper storage under nitrogen and in dark glass containers extends shelf life and prevents oxidation.
Most reputable suppliers offer menatetrenone at purities exceeding 98% for pharmaceutical grades, ensuring no significant contamination from related naphthoquinones or heavy metals. Specs call for strict limits on residual solvents, heavy metals (usually below 10 ppm), and microbial content (often below 100 cfu/g). Capsules, tablets, and solutions list vitamin K2 content in micrograms, milligrams, or international units. Labels indicate excipients, dosing instructions, storage advice (cool, dry, and away from light), as well as the official pharmacopoeial name. Some countries require a warning regarding interference with anticoagulant medications, given the bleeding risk when combined with warfarin.
Producers go two main routes for making menatetrenone: microbial fermentation or total chemical synthesis. The fermentation method recruits Bacillus subtilis or other bacteria to convert phylloquinone into MK-4 during soybean or other plant substrate processing. The synthetic method takes 1,4-naphthoquinone and selectively builds the isoprene side chain in sequential reactions, achieving higher yields and greater batch reproducibility. Both methods need sophisticated chromatography steps to purify the product, since related isomers and residual solvents contaminate crude extracts. In my experience, fermentation demands tighter process controls to keep impurities and degradation low, but it appeals to those preferring “natural” products.
Menatetrenone’s naphthoquinone ring supports simple reductions, oxidations, and alkylations, while the isoprenoid tail invites cleavage and derivatization if scientists need to tag or radiolabel the molecule. Some research outfits design synthetic analogs with fluorine or methyl substitutions on the ring to tweak absorption and tissue distribution. The two ketone groups participate readily in redox cycling, a property linked to MK-4’s ability to regenerate reduced vitamin K and support the so-called vitamin K cycle during carboxylation of key proteins. Every modification needs safety re-evaluation, since small chemical tweaks can impact bioactivity, tissue targeting, or toxicity.
Common names include MK-4, vitamin K2-4, menatetrenone, and 2-methyl-3-all-trans-decaprenyl-1,4-naphthoquinone. Trade names like Glakay and Menatetrenon show up in regulatory filings, especially in Japanese or European settings. Some commercial supplements rely mostly on the “vitamin K2” or “MK-4” moniker, leaving detailed chemistry for the fine print. Retailers often bundle menatetrenone with other bone or cardiovascular supplements, attracting customers with broader claims around calcium, D3, and magnesium pairing.
Actual use in supplements and drugs follows strict quality protocols. Regulatory agencies require cGMP compliance, validated cleaning protocols, and traceability from raw material to finished good. Menatetrenone facilities measure airborne particulates, control cross-contamination, and verify every batch’s identity and purity. Safety data sheets warn about inhalation, skin or eye irritation, and environmental disposal rules, mostly due to organic solvent use. Workers gear up with gloves, goggles, and lab coats during open handling. No product enters the market without passing stability, identity, and microbial contamination tests. Adverse event monitoring remains ongoing, so manufacturers constantly re-evaluate risk based on new clinical and post-market reports.
Prescription use spans osteoporosis treatment and prevention, especially in Japan and parts of Asia. Studies point to lower hip, vertebral, and non-vertebral fracture rates with long-term MK-4 intake among older adults. Some researchers suggest that menatetrenone slows arterial calcification and supports vascular elasticity—a potential game-changer for cardiovascular health, though not all regulatory agencies approve such claims. Dietary supplement makers market the compound to athletes, seniors, and anyone concerned about bone strength or arterial age, while niche veterinary and animal nutrition sectors experiment with it as well.
Laboratories worldwide continue probing menatetrenone’s full biological role. Investigators map out how different tissues (brain, pancreas, arteries, and bone) use MK-4 and why it outperforms other vitamin K types for specific conditions. New analytical tools let teams sniff out minor degradation products or metabolites, clearing up questions about true bioavailability and tissue distribution. Large-scale randomized studies include both healthy volunteers and high-risk populations, aiming to move MK-4’s use beyond osteoporosis into diabetes, cognitive decline, and even cancer support. Funding flows mostly from public health and pharmaceutical outfits, hoping that better understanding will inform both guidelines and product development.
Toxicity data from animal and clinical studies show menatetrenone as safe at both standard dietary and pharmacological doses, with rare reports of liver enzyme elevation and gastrointestinal discomfort in humans. Lifelong supplementation studies in rodents reveal high safety margins, though extreme doses, far beyond realistic intake, can stress the liver or worsen conditions if vitamin K antagonists like warfarin are used. Case reports from human trials confirm that MK-4 doesn’t prompt hypercoagulation in healthy users, though those on anticoagulants run significant risk of dosage disruption and possible clotting events. This risk spurs warnings and careful monitoring in clinical practice.
Ongoing research into menatetrenone holds real promise. Scientists look to develop more stable formulations, boosting oral uptake and tissue targeting, and larger trials may support claims in areas like cognitive decline, diabetes, and arterial aging. Teams chase low-cost synthetic strategies to make MK-4 affordable in low-resource settings, so emerging markets can access its bone-protective effects. Modern food tech also explores ways to fortify cuisines with safer, more effective forms of vitamin K2, aiming to knock down rates of osteoporosis and calcification-related disease globally. Regulatory standards will keep shifting in step with new evidence, shaping how menatetrenone gets used in medicine, supplements, and possibly even functional foods.
Menatetrenone, known as vitamin K2 or menaquinone-4, pops up in more conversations about bone health every year. You can find it sold as a supplement in health stores, but it came out of the lab for a reason: doctors in Japan use it as a therapy for osteoporosis and bone weakening. Japan’s Ministry of Health approved it long before most other places paid much attention to vitamin K2, and for good reason. Sometimes we hear about pharmaceuticals that turn out to do less than promised, but this isn’t just a hype story. Years of research have sketched out a solid argument for its benefits, especially in bone metabolism.
Every time someone eats dark leafy greens or natto, they get some vitamin K. Menatetrenone goes one step further. It acts on a protein called osteocalcin, which gets activated only in the presence of vitamin K2. Once turned on, osteocalcin helps glue calcium into the bone matrix. Without this switch, a lot of that calcium drifts through the bloodstream and ends up places it shouldn’t.
What always struck me is that modern diets easily leave us with enough vitamin K1 to clot blood, but not enough K2 for bones or arteries. Many people with healthy routines—walking, lifting, eating plenty of dairy—still see their bone density drop with age. Studies out of Japan and Europe show menatetrenone can actually dial back bone thinning and lower the odds of breaking a hip. Journal articles put numbers to this: daily MK-4 supplements around 45 mg have helped reduce fracture rates among elderly women who already had bone loss.
Research talks louder than theory. A review from “Osteoporosis International” pooled results from more than ten clinical trials and found that menatetrenone helped improve bone mineral density, especially for those who had osteoporosis after menopause. Some trials even recorded fewer spine and hip fractures over two to three years. Not every study winds up with clear wins, but the pattern is hard to ignore.
Doctors also study vitamin K2’s role beyond just bones. People who take long-term steroids, or who lose bone for specific medical reasons, have also seen benefits. Beyond bones, some hope that better vitamin K2 intake might help keep arteries clear by preventing calcium buildup, although this is still up for more debate.
There’s a gap between good research and what happens in clinics. Even in countries where bone loss is common, menatetrenone isn’t available everywhere or covered by insurance. Pricing, access, and unfamiliarity with the supplement stop some older adults from even hearing about it. Doctors who didn’t train in Japan or Europe rarely bring it up unless a patient reads about it themselves.
Supplements are popular in the United States, but dosage matters and most over-the-counter options barely graze the amounts used in medical studies. The FDA hasn’t given its blessing for treating osteoporosis with menatetrenone. Nobody wins if people take too little and expect miracles.
Bringing menatetrenone into the conversation doesn’t solve everything. More doctors and nutritionists need training on the real differences between K1 and K2, and policy needs to catch up with solid science. People at risk—older adults, especially women—benefit most from clear advice based on up-to-date evidence. Until more large-scale studies roll out, the best bet stays the same: keep bones strong through a balanced diet, movement, and staying aware of what’s going on in the nutrition world. Menatetrenone’s story isn’t finished, but it deserves a real seat at the table.
Menatetrenone, a form of vitamin K2, pops up in conversations around bone health and blood clotting. It often gets prescribed in Japan for osteoporosis, and some supplement users in other countries take it in the hope of protecting their bones or arteries. The science points out benefits for certain groups, especially older adults dealing with bone loss. I’ve seen a handful of patients put on this vitamin when standard calcium and vitamin D supplements weren’t enough. Many folks want natural solutions, and Menatetrenone often wears that “natural” badge, but it’s still a drug with real effects.
Nausea, diarrhea, and a funny feeling in the gut show up in the literature more than anything else. I once spoke to a gentleman who swore by Menatetrenone for his joints, but he always took it with food to dodge a rolling stomach. That lines up with reports in medical circles. Some folks experience bloating or mild stomach cramps. Wild swings don’t usually happen, but it’s no stranger to minor gut issues.
Skin reactions sometimes come up. Rash and itching make an appearance in rare cases, usually mild and temporary. A handful of people say they face redness or swelling, though big studies show these happen infrequently.
High doses create a theoretical risk for people with blood clotting disorders or those on warfarin. Menatetrenone can work against blood thinners, making it trickier for doctors to keep blood levels steady. I’ve seen a few patients need blood tests more often because their vitamin K intake jumped. Anyone on anticoagulants needs to talk to their provider before touching this supplement. That part isn’t negotiable.
Allergic reactions rarely make news, but in medicine, even rare things demand respect. Swelling, trouble breathing, or chest tightness need fast attention. I’ve never seen this firsthand, but I always tell patients: strange symptoms after a new pill, get help.
Most people take Menatetrenone without serious trouble if they stay within typical doses. Side effects pop up in less than 10 percent of cases, with most being on the mild side. Those figures come from clinical trials with hundreds of participants. The risk of liver or kidney issues looks very low unless someone goes far beyond recommended doses. But combining it with other medications ramps up the risk, especially in older adults managing multiple prescriptions.
Patients should bring a full list of medications and supplements to each clinic visit. Doctors need that info to spot potential conflicts early. I suggest discussing any new supplement with a pharmacist too—they spot clashing prescriptions before trouble starts. Dose matters. More does not equal better in most cases. The recommended daily amount for osteoporosis sticks to a certain range, and big jumps don’t add value but might add problems.
Cutting corners by buying over-the-counter versions from questionable sources also introduces risk. Stay with reputable brands that back up their labels with testing. This advice holds for any supplement, but especially for those with potential to affect blood clotting or interact with common medications.
Menatetrenone gives some people a real benefit for bone health, but no supplement or medication comes risk-free. Gut upset, minor rashes, and the rare but real risk of drug interactions all deserve attention. Taking it responsibly, with expert advice, gives the best chance for benefit without adding new worries.
Menatetrenone, also known as vitamin K2 (MK-4), plays a role far beyond what many realize. It supports healthy bone density and manages calcium in the body. In my practice, I’ve seen questions arise anytime a supplement gets recommended for long-term use, so let’s break down what matters.
People often ask, "How much should I take?" Getting the amount right matters, since too little won’t have the desired effects, while too much risks side effects or interactions. Clinical studies have used a range of doses, but 45 mg per day stands out, divided into three doses of 15 mg. Spreading out the intake during meals helps with absorption, because Menatetrenone dissolves in fat, not water. Always take it with food that contains some fat—think avocados, nuts, or a well-balanced meal.
Not everyone should jump into taking Menatetrenone. People using blood thinners need to speak with their doctor before even picking up a bottle. The reason is simple: vitamin K interacts with common anticoagulant drugs, like warfarin, and this can lead to serious health consequences. Other folks with kidney or liver concerns need extra supervision, too. This is one of those moments where professional advice, not internet lore, keeps you safe.
Taking any supplement demands honest tracking. I always encourage periodic blood tests and check-ins with a healthcare provider. Vitamin K levels aren’t part of routine checkups, but they can matter for people with bone loss or frequent fractures. If taking other supplements—especially calcium or vitamin D—mention it to your doctor because they interact within the body.
Focus on reputable brands. Poor quality supplements run the risk of contamination and inaccurate dosing, which only makes it harder to trust your treatment. Part of due diligence means researching which companies test their products and offer certificates for quality.
Supplements fill a gap, not a meal plan. Diets rich in leafy greens, natto, eggs, and dairy provide natural forms of vitamin K. In regions where natto isn’t common, such as North America, some people face lower dietary vitamin K2—making supplements more relevant. Yet, the groundwork of strong bones starts in the kitchen.
High-dose supplementation can sometimes cause stomach upset. I’ve heard from patients dealing with light indigestion or a mild rash, which usually resolves once the dose is divided or taken with heavier meals. Severe allergic reactions remain rare, but knowing the signs—such as itching or swelling—prevents small problems from growing.
Research into Menatetrenone draws attention for osteoporosis management, especially among postmenopausal women. Countries like Japan include it as a standard medical treatment for bone health. In my opinion, that says something about its importance in a clinical setting, yet it’s not a standalone answer. Therapy often benefits from teamwork between prescribers, pharmacists, and patients, making education and regular check-ins essential.
Menatetrenone sounds technical, but at its core, it’s a form of vitamin K2. Not all K2 forms act the same, though. The term “vitamin K2” covers several related compounds called menaquinones, which come in different chain lengths. Menatetrenone goes by MK-4, a specific subtype of K2. In health stores, you’ll probably see supplements labeled “MK-4,” “MK-7,” or just “vitamin K2.” Menatetrenone is the chemical name for MK-4.
Many people learning about vitamin K focus on bone health or heart health. Vitamin K helps the body use calcium properly, making sure calcium stays out of your arteries and ends up in your bones, where it belongs. MK-4, or menatetrenone, has its own track record. Studies in Japan looked at high doses of menatetrenone to help people with bone problems, especially postmenopausal women. The clinical trials in the 1990s and 2000s showed that MK-4 could reduce fracture rates compared to not taking it at all.
I’ve spoken to several pharmacists and medical researchers who point out that not every K2 offers the same benefit at the same dose. MK-4 (menatetrenone) acts quickly and leaves the body faster. MK-7, found in fermented soy foods like natto, stays in the blood longer, so smaller amounts taken less often can do the trick. For folks researching supplements, that difference can change what they buy.
Vitamin bottles might just say “K2” without pointing out the subtype. People looking for a supplement without knowing whether it’s MK-4 or MK-7 could get results that don’t match what clinical studies found. Blood levels rise and fall at different rates depending on the form. In pharmacy, accuracy on these fine points keeps people safe and helps their health. Clinical guidelines in Japan now mention menatetrenone for osteoporosis, while Europe often looks at MK-7 or even vitamin K1 found in leafy greens.
The idea that “all K vitamins are the same” is a myth. A strong evidence base shows that both menatetrenone and MK-7 improve vitamin K levels in the body, but studies highlight that menatetrenone (MK-4) uses higher daily doses to get results. MK-7, on the other hand, works effectively at much lower doses, thanks to its longer half-life. In Japan, menatetrenone is a prescription drug, with clear dosing based on clinical results. MK-7 usually comes as an over-the-counter supplement in the US and Europe.
Doctors I’ve talked to often recommend looking at your diet first. Hard cheeses, natto, and some eggs supply MK forms, while leafy greens supply vitamin K1. People taking blood thinners like warfarin must speak with a health professional before changing vitamin K intake, since both K1 and K2 impact clotting. There’s no evidence that more is always better—in fact, too much can interfere with certain medications and conditions.
Sorting through supplement trends gets tricky. If a label just says “K2,” find out if it’s MK-4 or MK-7. Each does something a little different, and research backs both forms for certain conditions. Ask a healthcare provider if you’re unsure, especially if you have medical conditions or take prescriptions that react to vitamin K.
One thing helped me personally: looking up reliable studies and talking to professionals before starting anything new. That one step can prevent wasted time and money—and it might protect your health, too.
Menatetrenone, often known as vitamin K2, plays a big role in keeping bones strong and blood clotting on track. People turn to it for osteoporosis, especially in some Asian countries, and for general supplements in places where bone health turns into a worry with age. I started paying attention when a friend on long-term warfarin therapy asked if adding K2 would mess with her blood thinner. That was a smart question — and points to a wider issue. Many vitamins get tossed into shopping carts with barely a thought given to drug interactions.
The most well-known risk sits with blood thinners, especially warfarin. Warfarin works by reducing the action of vitamin K in the body, slowing blood clot formation. Menatetrenone essentially adds more vitamin K, which can lower the effectiveness of warfarin. Studies point out that vitamin K supplements can shorten the prothrombin time, reducing the blood-thinning effect. Doctors see this in real life too, where adding K2 leads to higher clotting risk for folks relying on warfarin’s protection. This is no minor side effect. Strokes and clots carry heavy consequences. With an aging population, warfarin and other anticoagulants show up in medicine cabinets everywhere — so the overlap between prescriptions and over-the-counter vitamins grows every year.
Doctors usually recommend keeping vitamin K intake steady if you’re taking warfarin, not swinging up and down, which could throw off blood work and require dose changes. Unstable intake means lab visits, worries, and extra costs — all avoidable. Letting your doctor know about any supplement, especially K2, helps keep things on track. I can’t count the times I’ve heard people say, "It’s just a vitamin, it can’t hurt." That kind of thinking gets folks into trouble. Our bodies treat vitamins as active chemicals — and with K2, the evidence is real and measurable.
Beyond blood thinners, data on K2 interactions remain thin. Some concern exists for drugs like antibiotics, as antibiotics can wipe out gut bacteria that make K2, changing levels in your body. Hepatic drugs and those affecting bile flow might also shift how well K2 gets absorbed, though firm clinical reports are limited. While prescription drugs for cholesterol like orlistat and some bile acid sequestrants may reduce absorption of fat-soluble vitamins including K2, the evidence is sparser than with warfarin. It draws a line under the reality: not everything gets studied to the same standard, so we need to lean on established risk, case reports, and common sense until bigger studies catch up.
The world pushes more health supplements each year, promising longer life and stronger bones. Menatetrenone makes bold claims and carries some proven benefit in the right context. Yet, that benefit can turn upside down with a single overlooked prescription. Anyone on long-term medication — especially blood thinners — deserves a complete talk with their prescriber or pharmacist before adding K2. Pharmacist consultations don’t cost anything at most pharmacies, and yet, they offer a powerful check against hidden risks. Above all, the urge to hide supplements or brush over them during a check-up poses a real danger, not just for K2, but for any vitamin.
Knowledge spreads far beyond medical journals. Direct, open conversations between patients and healthcare professionals tackle the bulk of mistakes before they ever happen. With menatetrenone and similar vitamins, that approach won’t change anytime soon.
| Names | |
| Preferred IUPAC name | 3-methyl-2-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]naphthalene-1,4-dione |
| Pronunciation | /ˌmɛ.nə.tɛˈtriː.noʊn/ |
| Identifiers | |
| CAS Number | 863-61-6 |
| Beilstein Reference | 1204293 |
| ChEBI | CHEBI:76273 |
| ChEMBL | CHEMBL2107651 |
| ChemSpider | 3176 |
| DrugBank | DB01022 |
| ECHA InfoCard | 100.013.349 |
| EC Number | 'EC 4.1.1.32' |
| Gmelin Reference | 754621 |
| KEGG | C16744 |
| MeSH | D017929 |
| PubChem CID | 5282389 |
| RTECS number | QT1275000 |
| UNII | Q40Q9N063P |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C31H40O2 |
| Molar mass | 444.651 g/mol |
| Appearance | yellow to orange crystalline powder |
| Odor | Odorless |
| Density | 1.04 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 2.85 |
| Vapor pressure | 1.65E-10 mmHg |
| Acidity (pKa) | 17.56 |
| Basicity (pKb) | 8.40 |
| Magnetic susceptibility (χ) | -6100.0E-6 cm³/mol |
| Refractive index (nD) | 1.047 |
| Viscosity | 2.5 cP (20°C) |
| Dipole moment | 3.0961 D |
| Thermochemistry | |
| Std enthalpy of combustion (ΔcH⦵298) | -7715.8 kJ/mol |
| Pharmacology | |
| ATC code | A11CC02 |
| Hazards | |
| Main hazards | May cause eye, skin, and respiratory irritation. |
| Pictograms | 人体健康危害 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | Precautionary statements: P264, P270, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | Health: 1, Flammability: 1, Instability: 0, Special: |
| Flash point | 230.5 °C |
| Autoignition temperature | Autoignition temperature: 410°C |
| Lethal dose or concentration | LD50 intravenous mouse 570 mg/kg |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 45 mg daily |
